Abstract:
PROBLEM TO BE SOLVED: To provide a medicine useful for the treatment of a disease or a pathological state which is known that the disorder of endothelial function is the cause of the disease and/or the mechanism of worsening the disease because the medicine can limit the disorder of the endothelial function or the reduction of ability for utilizing the blood vessel. SOLUTION: The compound represented by formula (I) [wherein, V is a single bond or the like; M is a single bond or the like; A and E are each a nitrogen atom or the like; R3 is an aryl or a heteroaryl A group which may be substituted as necessary; Y is an aryloxy which may be substituted as necessary or the like], the isomer, the hydrate, the solvate or the addition salt with a pharmaceutically acceptable acid are provided. The pharmaceutical composition containing the compound is also provided.
Abstract:
PROBLEM TO BE SOLVED: To provide a compound which can restrain endothelium malfunction and the drop in possible use of NO by blood vessels, and is useful for the treatment of the crisis and expansion of the legion of atherosclerosis, the prevention of diseases complicated with it, the prevention of a blood vessel complication after blood vessel bypass, vasodilation, blood vessel re-circulation and heart transplantation, the treatment of cardiac muscle or peripheral ischemia, cardiac incompetence and pulmonary hypertension. SOLUTION: The compound represented by formula (1) [X is a 5 to 12-membered heterocyclic group or the like; n is 0 or 1; R1 is hydrogen atom or the like; Ra is single bond or the like; A is nitrogen atom or the like; E is nitrogen atom or the like; Rb is single bond or the like; W is an aryl or the like] and its optical isomer, its hydrate, its solvate and its addition salt with a pharmaceutically acceptable acid are included.
Abstract:
The invention relates to compounds having formula (I), wherein: R1 represents a hydrogen atom or a group selected from cycloalkyl, benzyl and alkyl, optionally substituted; R2, R3, R4 and R5 each represent a hydrogen atom or a hydroxy, methyl, -OSO2R10, -OCOR10, alkoxy group, optionally substituted, or R2 and R3,or R3 and R4, or R4 and R5 together form a group -O-(CH2)q-O-, -O-CH=CH-O- or -O-CH=CH-; R6, R7, R8 and R9 each represent a hydrogen atom or an alkoxy group, or R6 and R7, or R7 and R8, or R8 and R9 together form a group -O-(CH2)q-O-; R10 a group selected from linear or branched alkoxy C1-C6, NR11R'11,and alkyl, optionally substituted; R11 and R'11 each represent a hydrogen atom or an alkyl group, or R11 and R'11 together with the nitrogen atom bearing same form an optionally substituted mono- or bi-cyclic nitrogenous heterocycle; - X represents O, NH or CH2; m and p each represent 0 or 1; n and q each represent 1 or 2, said compound being in racemic form or in the form of optical isomers, as well as the pharmaceutically acceptable acid addition salts thereof. The invention is suitable for use in drugs.
Abstract:
Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.
Abstract:
The invention relates to novel isoquinoline derivatives of formula (I), to the synthesis thereof, and to the use of same in the prevention and/or treatment of pathologies resulting from the activation of the RhoA/ROCK pathway and the phosphorylation of the light chain of myosin. X represents a group -C(=0)-, -CH(OH)- or -CH
Abstract:
L'invention concerne de nouveaux dérivés isoquinoléines de formule (I), leur synthèse et leur utilisation dans la prévention et/ou le traitement de pathologies qui résultent de l'activation de la voie RhoA/ROCK et de la phosphorylation de la chaîne légère de la myosine. X représente un groupement -C(=0)-, -CH(OH)- ou -CH2-, et les autres substituants représentent des groupements variés tels que définis dans la revendication 1.
Abstract:
L'invention concerne de nouveaux dérivés isoquinoléines de formule (i), leur synthèse et leur utilisation dans la prévention et/ou le traitement de pathologies qui résultent de l'activation de la voie rhoa/rock et de la phosphorylation de la chaîne légère de la myosine. X représente un groupement -c(=0)-, -ch(oh)- ou -ch